{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:17:13Z","timestamp":1763644633219,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bone.2025.117501","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:11:32Z","timestamp":1745899892000},"page":"117501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Rebound hypercalcaemia timing is associated with cumulative weight-based denosumab dose for central giant cell granuloma treatment in children despite a dose weaning regimen"],"prefix":"10.1016","volume":"197","author":[{"given":"Alexander D.","family":"Chesover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Allgrove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Calder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmeline","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kshitij","family":"Mankad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon","family":"McBayDoherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dearbhla","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2025.117501_bb0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.tripleo.2007.04.003","article-title":"Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options","volume":"104","author":"de Lange","year":"2007","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"issue":"9","key":"10.1016\/j.bone.2025.117501_bb0010","article-title":"Evaluating treatment modalities for reducing recurrence in central giant cell granuloma: a narrative review","volume":"12","author":"Aliu","year":"2024","journal-title":"Dent. J. (Basel)"},{"issue":"6","key":"10.1016\/j.bone.2025.117501_bb0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/PAS.0000000000001257","article-title":"Giant cell lesions of the maxillofacial skeleton express RANKL by RNA in situ hybridization regardless of histologic pattern","volume":"43","author":"Stagner","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.bone.2025.117501_bb0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1034\/j.1600-0714.2003.00126.x","article-title":"Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts","volume":"32","author":"Liu","year":"2003","journal-title":"J. Oral Pathol. Med."},{"issue":"12","key":"10.1016\/j.bone.2025.117501_bb0025","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bone.2025.117501_bb0030","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1097\/SCS.0000000000007112","article-title":"Pediatric mandibular central giant cell granuloma: neoadjuvant immunotherapy to minimize surgical resection","volume":"32","author":"Lin","year":"2021","journal-title":"J. Craniofac. Surg."},{"author":"Joint Formulary Committee","key":"10.1016\/j.bone.2025.117501_bb0035"},{"issue":"3","key":"10.1016\/j.bone.2025.117501_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.21037\/tp-22-276","article-title":"Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review","volume":"12","author":"Wang","year":"2023","journal-title":"Transl. Pediatr."},{"issue":"5","key":"10.1016\/j.bone.2025.117501_bb0045","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/clinem\/dgad657","article-title":"Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document","volume":"109","author":"Vanderniet","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2025.117501_bb0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2025.117501_bb0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fped.2020.00515","article-title":"Case report: safety and efficacy of denosumab in four children with Noonan syndrome with multiple giant cell lesions of the jaw","volume":"8","author":"Ferriero","year":"2020","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.bone.2025.117501_bb0060","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2025.117501_bb0065","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"3","key":"10.1016\/j.bone.2025.117501_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28778","article-title":"Treatment of central giant cell granuloma in children with denosumab","volume":"68","author":"Choe","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.bone.2025.117501_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29436","article-title":"Treatment of central giant cell granuloma with denosumab: a case report of a complicated treatment course","volume":"69","author":"Brijs","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.bone.2025.117501_bb0080","article-title":"Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient","volume":"1","author":"Gandolfi","year":"2023","journal-title":"JCEM Case Rep."},{"issue":"1","key":"10.1016\/j.bone.2025.117501_bb0085","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"1","key":"10.1016\/j.bone.2025.117501_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-019-1197-z","article-title":"Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort","volume":"14","author":"Hoyer-Kuhn","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.bone.2025.117501_bb0095","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1210\/clinem\/dgad732","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta-the first prospective comparative study","volume":"109","author":"Liu","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117501_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116395","article-title":"Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre","volume":"159","author":"Vanderniet","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117501_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115048","article-title":"Off-label uses of denosumab in metabolic bone diseases","volume":"129","author":"Polyzos","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2025.117501_bb0110","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117501_bb0115","article-title":"Challenges in long-term control of hypercalcaemia with denosumab after haematopoietic stem cell transplantation for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis","volume":"14","author":"Taylor-Miller","year":"2021","journal-title":"Bone Rep."},{"issue":"18","key":"10.1016\/j.bone.2025.117501_bb0120","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMc1206193","article-title":"Denosumab for post-transplantation hypercalcemia in osteopetrosis","volume":"367","author":"Shroff","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2025.117501_bb0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00223-021-00935-z","article-title":"Clinical and radiologic response of central giant cell granuloma to denosumab: a 6-year prospective observational study","volume":"110","author":"Rhou","year":"2022","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"10.1016\/j.bone.2025.117501_bb0130","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2025.117501_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10210","article-title":"Use of denosumab in children with osteoclast bone dysplasias: report of three cases","volume":"3","author":"Upfill-Brown","year":"2019","journal-title":"JBMR Plus"},{"issue":"Supplement_2","key":"10.1016\/j.bone.2025.117501_bb0140","first-page":"ii1","article-title":"P80. Follow-up of 13 paediatric patients treated with Denosumab and Zoledronate for Aneurysmal Bone Cyst (ABC). Abstracts of the 11th International Conference on Children\u2019s Bone Health","volume":"8","author":"Jacobs","year":"2024","journal-title":"JBMR Plus"},{"issue":"5","key":"10.1016\/j.bone.2025.117501_bb0145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the denosumab-induced rebound phenomenon with alternating short- and long-acting anti-resorptive therapy in a young boy with severe OI type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117501_bb0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.bone.2025.117501_bb0155","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bone.2025.117501_bb0160","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00198-021-06002-5","article-title":"Denosumab for the treatment of primary pediatric osteoporosis","volume":"32","author":"Anastasilakis","year":"2021","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:47:26Z","timestamp":1762660046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S8756328225001139"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117501","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebound hypercalcaemia timing is associated with cumulative weight-based denosumab dose for central giant cell granuloma treatment in children despite a dose weaning regimen","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117501"}}